CA
NZ
UK
AU
IND
US
Novartis AG acquired a new radioligand cancer-therapy candidate from BoomRay Therapeutics, a China-based biotech led by Chief Executive Bo Shan, Ph.D., in a deal structured as an upfront payment plus up to USD 900 million in additional milestone andRoyaltypayments. Radioligand therapy, which combines a …
Novo Nordisk A/S Chief Executive Mike Doustdar told the Financial Times the company is weighing a direct listing on the New York Stock Exchange, comments that came through a media interview rather than a formal filing, meaning the plan remains at an exploratory stage …
Roche Holding AG reported positive phase 3 results for sefaxersen, formerly known as IONIS-FB-LRx, in patients with IgA nephropathy, a kidney disease, from the company's IMAGINATION study conducted inPartnershipwith Ionis Pharmaceuticals, Inc.. Jay Garg, M.D., Roche's global head of nephrology, rheumatology, and cardiovascular, said …
Eli Lilly and Company signed a discovery collaboration with Beijing-based InnoCare Pharma Limited covering up to five distinct drug targets spanning GLP-1 and obesity-diabetes therapeutics, BTK inhibition, bispecific antibodies, and broader cancer immunology, a breadth of coverage that reflects Lilly's interest in tapping into …
Eli Lilly and Company captures roughly 70 percent of the surging Medicare GLP-1 obesity and diabetes drug market, with the program now reaching approximately 700,000 seniors, and CEO David Ricks telling CNBC in an interview the week of September 21, 2026 that the company's …
Enveda Therapeutics, an AI-driven drug discovery biotech led by Chief Executive Officer Viswa Colluru, closed a USD 311 million Series E funding round led by Catalio Capital Management, with Iconiq among the other participating investors, valuing the company at USD 2 billion. A raise …
The Department of War awarded USD 47 million over five years to Apriori Bio and Prologue Medicines, two portfolio companies ofVenture Capitalfirm Flagship Pioneering, under the department's OnTarget program, with the contract structured to include an option for adding further Flagship-backed projects over time. …
Immunovant, Inc. terminated its cutaneous lupus erythematosus program for IMVT-1402, an FcRn-blocker, after the drug missed its primary endpoint in a phase 2b proof-of-concept trial, even though the data showed some positive trends that fell short of statistical significance for the primary measure. Shares …
Bristol Myers Squibb Company announced 265 moreJobcuts at its Princeton, New Jersey headquarters, the third distinct round of New Jersey layoffs during 2026, following earlier cuts of 247 positions in February and 206 positions in April, bringing the year's total New Jersey job reductions …
Celldex Therapeutics, Inc. reported positive results from two phase 3 trials of its monoclonal antibody barzolvolimab in chronic spontaneous urticaria, a chronic hives condition, with EMBARQ-CSU1 enrolling 963 patients and EMBARQ-CSU2 enrolling 976 patients. At 12 weeks, complete response rates, defined as a UAS7 …
Please wait processing your request...